Vaxart Inc Watch

from 8-K 50 pages Vaxart, Inc. 16,000,000 Shares of Common Stock Underwriting Agreement

from 8-K 44 pages Controlled Equity Offeringsm Sales Agreement

from 8-K 44 pages Open Market Sale Agreementsm

from S-3ASR 44 pages Vaxart, Inc. Shares of Common Stock ($0.0001 Par Value Per Share) Sales Agreement

from S-1/A 46 pages Vaxart, Inc. [·] Shares of Common Stock Pre-Funded Warrants to Purchase [·] Shares of Common Stock Common Warrants to Purchase [·] Shares of Common Stock Underwriting Agreement

from S-1/A 46 pages Vaxart, Inc. [·] Shares of Common Stock Pre-Funded Warrants to Purchase [·] Shares of Common Stock Common Warrants to Purchase [·] Shares of Common Stock Underwriting Agreement

from S-3 43 pages Vaxart, Inc. Common Stock (Par Value $0.10 Per Share) at Market Issuance Sales Agreement

from SC 13D ~5 pages Joint Filing Agreement

from SC 13D ~5 pages Joint Filing Agreement

from 8-K 36 pages Common Stock Biota Pharmaceuticals, Inc. Underwriting Agreement

from DFAN14A ~10 pages Schedule 13d/a - Seventh Amendment

from DFAN14A ~5 pages Schedule 13d/a - Sixth Amendment

from SC 13D 1 page Exhibit 1 Joint Filing Agreement Pursuant to Rule 13d-1(k)(1) the Undersigned Acknowledge and Agree That the Foregoing Statement on Schedule 13d Is Filed on Behalf of Each of the Undersigned and That All Subsequent Amendments to This Statement on Schedule 13d Shall Be Filed on Behalf of Each of the Undersigned Without the Necessity of Filing Additional Joint Filing Agreements. the Undersigned Acknowledge That Each Shall Be Responsible for the Timely Filing of Such Amendments, and for the Completeness and Accuracy of the Information Concerning It Contained Therein, but Shall Not Be Responsible for the Completeness and Accuracy of the Information Concerning the Others, Except to the Extent That It Knows or Has Reason to Believe That Such Information Is Inaccurate. This Agreement May Be Executed in Any Number of Counterparts and All of Such Counterparts Taken Together Shall Constitute One and the Same Instrument. Dated: April 17, 2006 Third Point LLC By: /S/ Daniel S. Loeb Name: Daniel S. Loeb Title: Chief Executive Officer Third Point Offshore Fund, Ltd. By: /S/ Daniel S. Loeb Name: Daniel S. Loeb Title: Director /S/ Daniel S. Loeb Daniel S. Loeb [Joint Filing Agreement for Schedule 13d With Respect to NABI Biopharmaceuticals]

from S-3/A 22 pages 8,500,000 Shares NABI Biopharmaceuticals Common Stock Underwriting Agreement

from S-3 28 pages 8,500,000 Shares NABI Biopharmaceuticals Common Stock Underwriting Agreement

from 8-K 1 page <page> 1 Exhibit 1 September 15, 1999 Securities and Exchange Commission, Mail Stop 11-3 450 Fifth Street, N.W. Washington, D.C. 20549 Commissioners: We Have Read the Statements Made by NABI (Copy Attached), Which We Understand Will Be Filed With the Commission, Pursuant to Item 4 of Form 8-K, as Part of the Company's Form 8-K Report Dated September 15, 1999. We Agree With the Statements Concerning Our Firm in Such Form 8-K. Very Truly Yours, /S/ Pricewaterhousecoopers Llp Pricewaterhousecoopers Llp